Earnings Conference Call to be held on November 13, 2007 at 8:00 am (Eastern) / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong)
SHANGHAI, China, Oct. 24 /Xinhua-PRNewswire/ -— WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech" or "the Company"), the leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release unaudited financial results for the third quarter ended September 30, 2007 after the US market closes on Monday, November 12, 2007.
The earnings release will be available on the investor relations page of its website at http://www.wuxipharmatech.com.
Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong) on Tuesday, November 13, 2007 to discuss its 2007 third quarter financial results and recent business activity. The conference call may be accessed by calling:
Toll Free Toll
United States +1-866-316-1369 +1-913-981-4915
China, Northern Region +10-800-714-0970
China, Southern Region +10-800-140-0945
Hong Kong +800-965-503
United Kingdom +0-800-051-7166
A telephone replay will be available shortly after the call until December 12, 2007 at (US) +1-888-203-1112/ (UK) +0-808-101-1153 / (HK) +800-901-108. Passcode: 7947278.
A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxipharmatech.com.
About WuXi PharmaTech
Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com.
For more information, please contact:
Investor Contact:
Dr. Hai Mi
Vice President, Corporate Communications
WuXi PharmaTech Co., Ltd
Tel: +86-21-5046-3726
Email: ir@pharmatechs.com
Investor Relations (US):
Mahmoud Siddig
Director
Taylor Rafferty
Tel: +1-212-889-4350
Email: Pharmatechs@taylor-rafferty.com
Investor Relations (HK):
Ruby Yim
Managing Director
Taylor Rafferty
Tel: +852-3196-3712
Email: Pharmatechs@taylor-rafferty.com
Media Contact:
John Dooley
Taylor Rafferty
Tel: +1-212-889-4350
Email: Pharmatechs@taylor-rafferty.com
